Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,368 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
116
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more
Conditions
Asthma
Interventions
Fluticasone furoate 50mcg, Fluticasone propionate 100mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Los Angeles, California • Rolling Hills Estates, California • Sacramento, California + 17 more
Conditions
Moderate to Severe Glabellar Lines
Interventions
Corabotase, Placebo
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 13 more
Conditions
High Grade Glioma, CNS Tumor
Interventions
Entrectinib, Cyclophosphamide, Etoposide, Carboplatin, G-CSF, Pegfilgrastim, Surgery
Drug · Biological · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 3 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Cystic Fibrosis
Interventions
Ciprofloxacin (Cipro Inhale, BAYQ3939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
58
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 47 more
Conditions
Prostatic Neoplasms
Interventions
Doxorubicin, Ketoconazole, Docetaxel, Estramustine, Degarelix
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pneumonia
Interventions
Ketogenic feeding, Standard feeding
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma
Interventions
DANYELZA, Sargramostim, Cytoxan, Topotecan, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Carboplatin, Irinotecan, Temozolomide, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Months to 19 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Type2 Diabetes Mellitus, Hypertension, PreDiabetes, Overweight and Obesity
Interventions
DASH diet, Very low carbohydrate, ketogenic diet, Extras
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Type 2 Diabetes
Interventions
Placebo, Survodutide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
89
States / cities
Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 81 more
Conditions
Multiple Myeloma
Interventions
Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone, Stem cell collection, Melphalan, G-CSF, Cyclophosphamide, Mesna
Procedure · Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Venous Leg Ulcer (VLU)
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Conditions
Cow's Milk Allergy
Interventions
Experimental Extensively Hydrolyzed Formula, Placebo Extensively Hydrolyzed Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
3 Months to 12 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Chicago, Illinois + 6 more
Not listed Not applicable Interventional

Zypan Functional Dyspepsia

NCT06320379
Conditions
Dyspepsia
Interventions
Zypan, Placebo Comparator
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Peripheral T-Cell Lymphoma
Interventions
Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection, Granulocyte-colony stimulating factor (G-CSF), Pegfilgrastim, Cyclophosphamide, Vincristine, Leucovorin, Methotrexate, Doxorubicin Hydrochloride, Cytarabine, Etoposide, Carmustine, Denileukin diftitox
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Decitabine, Filgrastim, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Terminated Phase 2 Interventional Results available

High Dose Intravenous Ascorbic Acid in Severe Sepsis

NCT02734147
Conditions
Sepsis
Interventions
Ascorbic Acid, Normal Saline
Drug · Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Conditions
Cardiovascular Disease
Interventions
Peanuts, Glucose and whipping cream, Oil Blend
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
University Park, Pennsylvania
Conditions
Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma
Interventions
Pembrolizumab, Etoposide, Ifosfamide, Mesna, Carboplatin, Brentuximab vedotin, Rituximab
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Goodyear, Arizona
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Delphinol® Dose on Vascular Function

NCT07196059
Conditions
Healthy
Interventions
Delphinol, Placebo
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Memphis, Tennessee
Completed Not applicable Interventional Accepts healthy volunteers

Embracing Morning BReakfast and Activity for Classroom Engagement

NCT06555627
Conditions
Child Development
Interventions
High Protein Breakfast, Morning Exercise, High Carb Breakfast
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
6 Years to 11 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Methylprednisolone, Pharmacological Study, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Vincristine Sulfate
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 22 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
182
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 140 more
Conditions
Lactose Intolerance
Interventions
RP-G28, Placebos
Drug
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
35
States / cities
Birmingham, Alabama • Chula Vista, California • Huntington Park, California + 31 more
Conditions
Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Interventions
Radiation Therapy Boost, Pembrolizumab, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine
Radiation · Drug
Lead sponsor
Laura M. Spring, MD
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more